



American Society of Clinical Oncology – Genitourinary Cancers Symposium (ASCO GU) 2022; San Francisco, California (Hybrid): Eisai Inc. Sponsored Research

Please see the listing of Eisai Inc. sponsored research presented at ASCO GU 2022 below.

RENAL CELL CARCINOMA

1. Choueiri TK, Plimack ER, Powles T, et al. Phase 3 Study of First-line Treatment with Pembrolizumab + Belzutifan + Lenvatinib or Pembrolizumab-quavonlimab + Lenvatinib Versus Pembrolizumab + Lenvatinib for Advanced Renal Cell Carcinoma. Poster presented at the ASCO Genitourinary Cancers Symposium (ASCO GU); February 17-19, 2022; San Francisco, California (Hybrid).
2. Lee CH, Rasco D, Rao A, et al. Association Between Biomarkers and Clinical Outcomes of Lenvatinib Plus Pembrolizumab in Advanced Renal Cell Carcinoma: Results from KEYNOTE-146/Study 111. Poster presented at the ASCO Genitourinary Cancers Symposium (ASCO GU); February 17-19, 2022; San Francisco, California (Hybrid).
3. Rha SY, Choueiri TK, Matveev VB, et al. Efficacy and Safety of Lenvatinib Plus Pembrolizumab Versus Sunitinib in the East Asian Subset of Patients With Advanced Renal Cell Carcinoma from the Phase 3 CLEAR Trial. Poster presented at the ASCO Genitourinary Cancers Symposium (ASCO GU); February 17-19, 2022; San Francisco, California (Hybrid).
4. Motzer R, Albiges L, Choueiri TK, et al. Phase 1b/2 Umbrella Study of Investigational Immune and Targeted Combination Therapies for Patients with Advanced Clear Cell Renal Cell Carcinoma. Poster presented at the ASCO Genitourinary Cancers Symposium (ASCO GU); February 17-19, 2022; San Francisco, California (Hybrid).

UROTHELIAL CANCER

1. Loriot Y, Grivas P, de Wit R, et al. First-line Pembrolizumab With or Without Lenvatinib in Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-blind Study. Oral presentation at the ASCO Genitourinary Cancers Symposium (ASCO GU); February 17-19, 2022; San Francisco, California (Hybrid).

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the publication(s) listed above, please submit your request via www.eisaimedicalinformation.com/oncology/medicalinquiry or the submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_oncmedinfo@eisai.com or call 1-888-274-2378.